Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors

Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors
IMV will soon launch a Phase 2 trial to examine the potential of its lead candidate DPX-Survivac in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in five solid tumor types. The study is expected to include at least 200 patients with bladder, liver, ovarian, or non-small cell lung (NSCLC) cancers, as well as tumors positive for the microsatellite instability high (MSI-H) biomarker. Enrollment is expected to begin during the fourth quarter of 2018, across several clinical centers in Canada and the U.S. “With this new study evaluating the combination of IMV and Merck immunotherapies, our goal is to expand the patient impact and market potential of our lead candidate across a broad range of cancers,” Joseph Sullivan, senior vice president of business development at IMV, said in a press release. “The Merck team has significant experience in the field, and we are very enthusiastic about exploring this combination with them in multiple solid tumor indications.” DPX-Survivac is a cancer vaccine that triggers a strong immune response against the survivin protein. Survivin is broadly over-activated in most cancer types, playing an essential role in tumor growth and resistance to anti-cancer therapies. DPX-Survivac is meant to kill
Subscribe or to access all post and page content.